Cystoid macular oedema (CMO) Eye Diseases Other retinal disorders
Conditions
Interventions
1. Intervention: ketorolac eye drops (0.4%) - 1 eye drop 4 times a day for 3 days before the operation and 3 weeks after the operation
2. Control arm: usual clinical care - 1 drop of flurbiprofen eye
Sponsors
Frimley Park Hospital NHS Foundation Trust (UK)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients undergoing routine cataract surgery without an additional procedure 2. Patients with risk factors for developing CMO, such as pre-existing diabetes 3. Aged 18 to 75 years, male and female Patients with epiretinal membranes or age-related macular degeneration (ARMD) will be analysed separately.
Exclusion criteria
Exclusion criteria: 1. Patients who have previously had a reaction to ketorolac 2. Patients who are on systemic non-steroidal anti-inflammatories or steroids
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Central macula thickness as measured on optical coherence tomography at baseline (prior to surgery), 1 month after surgery, 2 months after surgery and 3 months after surgery. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Logarithmic minimal angle of resolution (LogMAR) visual acuity 2. Contrast sensitivity 3. Adverse events The secondary outcomes will be measured at baseline (prior to surgery), 1 month after surgery, 2 months after surgery and 3 months after surgery. | — |
Countries
United Kingdom
Outcome results
None listed